

CombinatoRx

[View the current CombinatoRx Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/21179-CombinatoRx.html>)

Contact Details:

245 First St. Sixteenth Floor
Cambridge
Massachusetts
02142
United States of America

Tel: 617-301-7000
Fax: 617-301-7010
Email: info@combinatorx.com

CombinatoRx, Incorporated is a biopharmaceutical company focused on developing new medicines built from synergistic combinations of approved drugs. In less than six years, we have discovered and advanced into clinical trials a portfolio of six product candidates targeting multiple immuno-inflammatory diseases and cancer, at a total investment, including development of our proprietary screening technology, of less than \$50 million

Recent Publications by CombinatoRx:



- [Synergistic drug combinations tend to improve therapeutically relevant selectivity.](#)
Drug combinations are a promising strategy to overcome the compensatory...29th September, 2009
CombinatoRx Inc., Cambridge, Massachusetts, USA.- *Nat Biotechnol.* 2009 Jul;27(7):659-66. Epub 2009 Jul 5. ([DOI Direct Link](#))
- [Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug.](#)
INTRODUCTION: Glucocorticoids are a mainstay of anti-inflammatory therapy,...10th September, 2009
CombinatoRx, Incorporated, First Street, Cambridge, MA 02142, USA.- *Arthritis Res Ther.* 2009;11(1):R12. Epub 2009 Jan 26. ([DOI Direct Link](#))
- [Biotransformation and in vitro assessment of metabolism-associated drug-drug interaction for CRx-102, a novel combination drug candidate.](#)
CRx-102 is an oral synergistic combination drug which contains the...2nd September, 2009
Department of Preclinical Development and Formulations, CombinatoRx Inc.,- *J Pharm Biomed Anal.* 2009 Sep 8;50(2):200-9. Epub 2009 Apr 19. ([DOI Direct Link](#))
- [Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantitation of prednisolone and dipyridamole in human plasma and its application in a](#)

[pharmacokinetic study.](#)

We have developed and validated an accurate, sensitive, and robust... 30th July, 2009
Department of Preclinical Development and Formulations, CombinatoRx, Inc.,- J Pharm Biomed Anal.
2009 Jul 12;49(5):1241-9. Epub 2009 Feb 25. ([DOI Direct Link](#))

• [Combination chemical genetics.](#)

Predicting the behavior of living organisms is an enormous challenge given... 17th December, 2008
CombinatoRx Incorporated, 245 First Street, Cambridge, Massachusetts- Nat Chem Biol. 2008
Nov;4(11):674-81. ([DOI Direct Link](#))

• [High-order combination effects and biological robustness.](#)

Biological systems are robust, in that they can maintain stable phenotypes... 17th October, 2008
Discovery, CombinatoRx- Mol Syst Biol. 2008;4:215. Epub 2008 Aug 5. ([DOI Direct Link](#))

• [The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action.](#)

Combination therapy has proven successful in treating a wide variety of... 23rd January, 2008
CombinatoRx, Incorporated, 245 First Street, 16th Floor, Cambridge, MA- Cancer Res. 2007 Dec
1;67(23):11359-67. ([DOI Direct Link](#))

• [CombinatoRx brings its molecular speed dating to Singapore.](#)

Combination therapy has proven successful in treating a wide variety of... 8th January, 2008
CombinatoRx Incorporated, Cambridge, MA, USA.- Biotechnol J. 2007 Nov;2(11):1325-6. ([DOI Direct Link](#))

• [Identification and characterization of two chloramphenicol glucuronides from the in vitro glucuronidation of chloramphenicol in human liver microsomes.](#)

This study reports the development of a specific and sensitive liquid... 7th December, 2007
Department of Pharmaceutical Sciences, Massachusetts College of Pharmacy- Xenobiotica. 2007
Sep;37(9):954-71. ([DOI Direct Link](#))

• [Multi-target therapeutics: when the whole is greater than the sum of the parts.](#)

Drugs designed to act against individual molecular targets cannot usually... 17th April, 2007
CombinatoRx Inc., 245 First Street, Cambridge, MA 02142, USA.- Drug Discov Today. 2007
Jan;12(1-2):34-42. Epub 2006 Nov 28. ([DOI Direct Link](#))

• [Chemical combination effects predict connectivity in biological systems.](#)

Efforts to construct therapeutically useful models of biological systems... 7th April, 2007
CombinatoRx, Incorporated, Cambridge, MA 02142, USA.- Mol Syst Biol. 2007;3:80. Epub 2007 Feb
27. ([DOI Direct Link](#))

• [Multicomponent therapeutics for networked systems.](#)

Therapeutic regimens that comprise more than one active ingredient are... 3rd March, 2005
CombinatoRx, Inc., 650 Albany Street, Boston, Massachusetts 02118, USA.- Nat Rev Drug Discov.
2005 Jan;4(1):71-8. ([DOI Direct Link](#))

• [Proteasome inhibition: a new anti-inflammatory strategy.](#)

The ubiquitin-proteasome pathway has a central role in the selective... 9th January, 2004
CombinatoRx Inc., Boston, Massachusetts, USA.- J Mol Med. 2003 Apr;81(4):235-45. Epub 2003 Mar
26. ([DOI Direct Link](#))

• [Systematic discovery of multicomponent therapeutics.](#)

Multicomponent therapies, originating through deliberate mixing of drugs... 2nd August, 2003
CombinatoRx Incorporated, 650 Albany Street, Boston, MA 02118, USA.- Proc Natl Acad Sci U S A.
2003 Jun 24;100(13):7977-82. Epub 2003 Jun 10. ([DOI Direct Link](#))

Press Releases on CombinatoRx:

CombinatoRx and Neuromed Sign Merger Agreement	2nd July, 2009	Neuromed Pharmaceuticals Ltd.	- Merger to Create a Sustainable Biotechnology Company: Brings Together Significant Product Assets, Unique Discovery Capabilities and Financial Resources - CAMBRIDGE, MA and PARIS, May 4 /PRNewswire/ --
Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis	4th May, 2009	Fovea Pharmaceuticals	Fovea Pharmaceuticals announced today positive results from its clinical proof-of-concept trial to assess the therapeutic effect of Prednisporin(TM) (FOV1101) in patients RESEARCH TRIANGLE PARK, N.C., Feb. 16 /PRNewswire/ --
AlphaVax Announces New Vice President of Regulatory, Quality and Clinical Operations	16th February, 2009	AlphaVax	AlphaVax announced today that it has hired Lynn Baird, PhD, as Vice President of Regulatory, Quality and Clinical Operations. In this capacity BEDFORD, Mass., Oct. 20 /PRNewswire-FirstCall/ --
Sally W. Crawford Joins Insulet's Board of Directors	20th October, 2008	Insulet Corporation	Insulet Corporation (Nasdaq: PODD), the leader in patch pump technology with its OmniPod(R) Insulin Management System, today announced the appointment
DANIOLABS SCREENING COMBINATION PRODUCTS FOR COMBINATORX IN INFLAMMATORY	1st October, 2003	Daniolabs	DANIOLABS SCREENING COMBINATION PRODUCTS FOR COMBINATORX IN INFLAMMATORY BOWEL DISEASE THE EFFECTS OF MODULATING

BioNews Results for CombinatoRx



- [Event Updates: Cell Therapeutics \(CTIC\), Human Genome Sciences \(HGS\), Poniard Pharmaceuticals \(PARD\), CombinatoRx \(CRXX\), Hemispherx Biopharma \(HEB\): Winners & Potential winner stocks](#)
EON: Nov 11 2009 4:09PM Matching: combinatorx
- [Agilent announces 2009 automation user group](#)
Laboratorytalk: Nov 11 2009 6:09AM Matching: combinatorx
- [BRIEF-CombinatoRx and Angiotech Pharmaceuticals terminate research and license agreement](#)

- FinanzNachrichten.de: Nov 10 2009 9:57PM Matching: combinatorx*
- [BRIEF-CombinatoRx and Angiotech Pharmaceuticals terminate research and license agreement](#)
Forbes.com: Nov 10 2009 10:02PM Matching: combinatorx
 - [BRIEF-CombinatoRx and Angiotech Pharmaceuticals terminate research and license agreement](#)
Interactive Investor International: Nov 10 2009 10:17PM Matching: combinatorx
 - [Job cuts help CombinatoRx narrow Q3 loss](#)
Mass High Tech: Nov 5 2009 12:17AM Matching: combinatorx
 - [CombinatoRx narrows loss on deep R&D cuts](#)
San Francisco Business Times: Nov 4 2009 12:17AM Matching: combinatorx
 - [CHP, CRXX, WOLF, FSI, HOLL, ATGN Expected To Be Higher Leading Up To Next Earnings Releases](#)
Pharmacy Choice: Nov 4 2009 7:19AM Matching: combinatorx
 - [Johnson & Johnson cutting 7,000 jobs; no word on Mass. impact](#)
Charlotte Business Journal: Nov 4 2009 1:35PM Matching: combinatorx
 - [CombinatoRx Reports Financial Results for the Third Quarter 2009](#)
SmartBrief: Nov 3 2009 8:50PM Matching: combinatorx
 - [CombinatoRx Reports Financial Results for the Third Quarter 2009](#)
Pharma Live: Nov 3 2009 4:52PM Matching: combinatorx
 - [Financial results for third-quarter 2009 announced by Combinatorx](#)
News-Medical.Net: Nov 3 2009 2:15PM Matching: combinatorx
 - [CombinatoRx Reports Financial Results for the Third Quarter 2009](#)
Forbes.com: Nov 3 2009 1:03PM Matching: combinatorx
 - [CombinatoRx Reports Financial Results for the Third Quarter 2009](#)
FinanzNachrichten.de: Nov 3 2009 12:40PM Matching: combinatorx
 - [CombinatoRx Reports Financial Results for the Third Quarter 2009](#)
Genetic Engineering News: Nov 3 2009 1:33PM Matching: combinatorx

CombinatoRx Clinical Trials:



- [Multicenter Active RA Study](#)

CombinatoRx Patents:



- 7335371- [Combinations for the treatment of inflammatory disorders](#)
- 7253155- [Combinations for the treatment of immunoinflammatory disorders](#)
- 7148216- [Combinations of drugs for the treatment of neoplastic disorders](#)
- 6955815- [Combinations for the treatment of inflammatory disorders](#)
- 6897206- [Combinations for the treatment of inflammatory disorders](#)

- 6846816- [Combinations of drugs for the treatment of neoplastic disorders](#)
- 6693125- [Combinations of drugs \(e.g., a benzimidazole and pentamidine\) for the treatment of neoplastic disorders](#)
- 6569853- [Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

